A recent retrospective cohort study showed that providing antiviral chemoprophylaxis to at least 70% of eligible residents in nursing homes within two days of outbreak detection reduced the risk of 14-day hospitalization.1
The US Centers for Disease Control and Prevention and the Infectious Diseases Society of America give a strong (A-III) recommendation for outbreak chemoprophylaxis, but that recommendation rests on data from small studies. The literature has not been clear on how quickly or how broadly oseltamivir prophylaxis needed to be deployed to change outcomes.
The new study, published in JAMA Internal Medicine, examined whether starting antiviral chemoprophylaxis in at least 70% of eligible residents in nursing homes within two days of detecting an influenza outbreak is linked to reduced all-cause mortality and hospitalizations. The study included 404 outbreaks across 318 nursing homes, with 35,086 resident-trial observations. Outcomes were all-cause death and hospitalizations within 14 and 30 days of outbreak detection.
Giving oseltamivir prophylactically to at least 70% of eligible residents within two days of outbreak detection was associated with a 21% relative risk reduction in 14-day all-cause hospitalization.1
“The results translate to roughly one hospitalization averted per 100 residents covered. However, mortality was not different at 14 or 30 days,” said Viren Kaul, MD, FCCP, Chief of Medicine at Crouse Health. “Coverage thresholds of 60% and 80% within two days produced similar benefit. The actionable message is not to aim for 100%; it is to reach the most residents in the first 48 hours.”
For facility medical directors and infection prevention teams, this turns a vague directive into a clear, measurable target: Detect local outbreaks early and administer oseltamivir to the most eligible residents possible within 48 hours. Dr. Kaul said that achieving this requires downstream supports such as standing orders, pre-approved protocols, onsite or same-day pharmacy supply, and staff authorized to act without waiting for individual prescriber approval.
“This can be an operational tall ask,” he said. “There is caution to be exercised: First, there is not a major mortality advantage, and second, we do not know how the results are confounded by facility quality. These need to be taken into consideration before any rollouts.”
Additional research will help, Dr. Kaul said, particularly a trial that standardizes co-interventions, which the authors of the recent cohort study acknowledge is preferable and difficult. A pragmatic stepped-wedge design in a large nursing home system, randomizing the outbreak response protocol rather than the drug, is one feasible approach.
Additionally, unit-level vs facility-wide prophylaxis needs to be studied. Other agents, such as baloxavir, also need to be studied to see whether a single-dose agent would yield better results than oseltamivir, which requires a longer course.
References
1. Silva JBB, Hsieh HT, Howe CJ, Gravenstein S, Reich LA, Zullo AR. Prompt and intensive antiviral chemoprophylaxis in nursing home influenza outbreaks. JAMA Intern Med. 2026;186(6):714-722. doi:10.1001/jamainternmed.2026.0401
